At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of the breast
- ✓Female, age >18 years
- ✓Normal cardiac function
- ✓Able to perform activities of daily living with minimal assistance
- ✕Life expectancy <6 months
- ✕History of significant heart disease
- ✕Prior chemotherapy or hormonal therapy (within 5 years)
- ✕Concurrent trastuzumab therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Epirubicin, and 1 other intervention for Breast Cancer. Completed, enrolled 110 participants.
Detailed Summary
Treatment strategies that include induction chemotherapy have several potential advantages: early initiation of systemic chemotherapy, in vivo assessment of response, and down-staging of both the primary tumor and regional lymphatic metastases, making breast conservation an option for many. The aim of the present study is to determine the efficacy and toxicity of induction combination chemotherapy with the triplet, gemcitabine, epirubicin, and docetaxel, in patients with locally advanced or inflammatory breast cancer. Clearly, it is in the upfront treatment as well as in the adjuvant treatment of breast cancer, that effective new agents and combination of agents are likely to have the greatest potential impact.
Study Details
Timeline
Interventions
Gemcitabine
Epirubicin
Docetaxel